share_log

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD:其他
SEC announcement ·  03/13 13:08
Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
美国证券交易委员会(SEC)已通知在美国上市的Intelligent Bio Solutions Inc.,其于2024年3月4日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会于2024年3月13日发给智能生物解决方案首席执行官哈里·西蒙尼迪斯的来文。美国证券交易委员会的信提醒该公司及其管理层,无论美国证券交易委员会的审查程序如何,他们都对披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。美国证券交易委员会的本杰明·里奇是该公司任何进一步询问的联系人。
美国证券交易委员会(SEC)已通知在美国上市的Intelligent Bio Solutions Inc.,其于2024年3月4日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会于2024年3月13日发给智能生物解决方案首席执行官哈里·西蒙尼迪斯的来文。美国证券交易委员会的信提醒该公司及其管理层,无论美国证券交易委员会的审查程序如何,他们都对披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。美国证券交易委员会的本杰明·里奇是该公司任何进一步询问的联系人。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息